Clinical Trial Search

Primary: Medically Attended Skin and Soft Tissue Infections (MA-SSI) — 20.9; 17 percentage of partipants

Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356

Primary: Measurement of Change in Cutibacterium Acnes — 3; 8; 3; 2 Participants — p=0.004

Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants

Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants

Primary: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae — 12.5; 7.2; 16.6; 9.3 percentage of participants

Primary: Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC) — 45; 16; 2 Participants

Primary: Children's Yale-Brown Obsessive Compulsive Scale Total Score — 20.59; 25.67 units on a scale — p=0.44

Primary: Skin Swab and Culture With Colony Forming Units (CFUs) — 39; 51; 35; 22 negative skin cultures — p=0.68

Primary: Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx — 12.6 Percentage of Participants

Primary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]

Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…

Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score

Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate

Primary: Number of Sick Days — p=< 0.05

Primary: Count of Participants With Positive Group B Streptococcus Rectovaginal Colonization Status at 35- 37 Weeks' Gestational Age — 20; 23 Participants — p=0.87

Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo

Primary: Rates of Staphylococcus Aureus Acquisition: Percentage of Short Stay Participants Who Acquired MRSA or MSSA (or Both) During the Study Period — 17; 8 Participants

Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants

Primary: Number of Participants With a Clinical Cure — 45; 42 Participants — p=0.71

Primary: Number of Participants Eradicated of S. Aureus Carriage - 1 Month After Intervention — 24; 35; 35; 34 Participants

Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035

Primary: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to Adverse Events (AEs) — 1 incidence

Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…

Primary: Visual Analog Scale(VAS) for Pain - Day 1 to 48 Hours — 79.64; 56.45; 39.71; 25.91 score on a scale

Primary: Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days — 18; 7 Participants

Primary: Number of Patients With a Major Cardiac Implantable Electronic Devices (CIED) Infection — 5; 6 Participants

Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants

Primary: Quantify the Tolerability of Tedizolid for Bone and Joint Infections, Both Hardware and Non-hardware Associated — 0; 0 participants

Primary: Number of Patients With Adverse Events (AEs) — 27 participants